Oobli receives ‘no-questions’ letter from FDA for its second sweet protein monellin
Oobli received a “no-questions” response letter from the FDA for its precision fermentation-derived monellin — the company’s second sweet protein to achieve Generally Recognized as Safe (GRAS) status this year.